Interrupting treatment of vulnerable people on immune-suppressing medicines doubles their antibody response to COVID-19 booster vaccination, NIHR

Interrupting the treatment of vulnerable people on long-term immune supressing medicines for two weeks after a COVID-19 booster vaccination can double their antibody response to the jab, new research finds. The VROOM trial will have implications for people on immune-supressing medicines, who are among the millions of clinically vulnerable patients advised to ' shield ' during the pandemic. The study, funded by an NIHR and the Medical Research Council (MRC) partnership, and led by researchers at the University of Nottingham, is now published in the journal Lancet Respiratory Medicine.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news